302 related articles for article (PubMed ID: 25215472)
1. Inflammatory response in Parkinson's disease (Review).
Yan J; Fu Q; Cheng L; Zhai M; Wu W; Huang L; Du G
Mol Med Rep; 2014 Nov; 10(5):2223-33. PubMed ID: 25215472
[TBL] [Abstract][Full Text] [Related]
2. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
3. Human neuromelanin induces neuroinflammation and neurodegeneration in the rat substantia nigra: implications for Parkinson's disease.
Zecca L; Wilms H; Geick S; Claasen JH; Brandenburg LO; Holzknecht C; Panizza ML; Zucca FA; Deuschl G; Sievers J; Lucius R
Acta Neuropathol; 2008 Jul; 116(1):47-55. PubMed ID: 18343932
[TBL] [Abstract][Full Text] [Related]
4. The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease.
Mirza B; Hadberg H; Thomsen P; Moos T
Neuroscience; 2000; 95(2):425-32. PubMed ID: 10658622
[TBL] [Abstract][Full Text] [Related]
5. Persistent phagocytic characteristics of microglia in the substantia nigra of long-term Parkinsonian macaques.
Barcia C; Ros CM; Ros-Bernal F; Gómez A; Annese V; Carrillo-de Sauvage MA; Yuste JE; Campuzano CM; de Pablos V; Fernández-Villalba E; Herrero MT
J Neuroimmunol; 2013 Aug; 261(1-2):60-6. PubMed ID: 23759319
[TBL] [Abstract][Full Text] [Related]
6. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation.
De Lella Ezcurra AL; Chertoff M; Ferrari C; Graciarena M; Pitossi F
Neurobiol Dis; 2010 Mar; 37(3):630-40. PubMed ID: 19969084
[TBL] [Abstract][Full Text] [Related]
7. Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease.
Collins LM; Toulouse A; Connor TJ; Nolan YM
Neuropharmacology; 2012 Jun; 62(7):2154-68. PubMed ID: 22361232
[TBL] [Abstract][Full Text] [Related]
8. Inflammation in Parkinson's disease.
Tufekci KU; Meuwissen R; Genc S; Genc K
Adv Protein Chem Struct Biol; 2012; 88():69-132. PubMed ID: 22814707
[TBL] [Abstract][Full Text] [Related]
9. The role of neuroinflammation on the pathogenesis of Parkinson's disease.
Chung YC; Ko HW; Bok E; Park ES; Huh SH; Nam JH; Jin BK
BMB Rep; 2010 Apr; 43(4):225-32. PubMed ID: 20423606
[TBL] [Abstract][Full Text] [Related]
10. Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation.
Teismann P; Schulz JB
Cell Tissue Res; 2004 Oct; 318(1):149-61. PubMed ID: 15338271
[TBL] [Abstract][Full Text] [Related]
11. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
Kim S; Moon M; Park S
J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
[TBL] [Abstract][Full Text] [Related]
12. Peli1 controls the survival of dopaminergic neurons through modulating microglia-mediated neuroinflammation.
Dai D; Yuan J; Wang Y; Xu J; Mao C; Xiao Y
Sci Rep; 2019 May; 9(1):8034. PubMed ID: 31142803
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-inflammatory therapy for Parkinson's disease.
Gao HM; Liu B; Zhang W; Hong JS
Trends Pharmacol Sci; 2003 Aug; 24(8):395-401. PubMed ID: 12915048
[TBL] [Abstract][Full Text] [Related]
14. Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson's disease: Potential clinical and therapeutic implications.
Angelopoulou E; Paudel YN; Shaikh MF; Piperi C
Pharmacol Res; 2020 Aug; 158():104930. PubMed ID: 32445958
[TBL] [Abstract][Full Text] [Related]
15. Updates on immunity and inflammation in Parkinson disease pathology.
Joshi N; Singh S
J Neurosci Res; 2018 Mar; 96(3):379-390. PubMed ID: 29072332
[TBL] [Abstract][Full Text] [Related]
16. Running exercise protects the substantia nigra dopaminergic neurons against inflammation-induced degeneration via the activation of BDNF signaling pathway.
Wu SY; Wang TF; Yu L; Jen CJ; Chuang JI; Wu FS; Wu CW; Kuo YM
Brain Behav Immun; 2011 Jan; 25(1):135-46. PubMed ID: 20851176
[TBL] [Abstract][Full Text] [Related]
17. Intranigral Administration of
Luna-Herrera C; Martínez-Dávila IA; Soto-Rojas LO; Flores-Martinez YM; Fernandez-Parrilla MA; Ayala-Davila J; León-Chavez BA; Soto-Rodriguez G; Blanco-Alvarez VM; Lopez-Salas FE; Gutierrez-Castillo ME; Gatica-Garcia B; Padilla-Viveros A; Bañuelos C; Reyes-Corona D; Espadas-Alvarez AJ; Garcés-Ramírez L; Hidalgo-Alegria O; De La Cruz-López F; Martinez-Fong D
J Immunol Res; 2020; 2020():5907591. PubMed ID: 33282962
[TBL] [Abstract][Full Text] [Related]
18. The potential role of neuroinflammation and transcription factors in Parkinson disease.
Tiwari PC; Pal R
Dialogues Clin Neurosci; 2017 Mar; 19(1):71-80. PubMed ID: 28566949
[TBL] [Abstract][Full Text] [Related]
19. Novel role of aquaporin-4 in CD4+ CD25+ T regulatory cell development and severity of Parkinson's disease.
Chi Y; Fan Y; He L; Liu W; Wen X; Zhou S; Wang X; Zhang C; Kong H; Sonoda L; Tripathi P; Li CJ; Yu MS; Su C; Hu G
Aging Cell; 2011 Jun; 10(3):368-82. PubMed ID: 21255222
[TBL] [Abstract][Full Text] [Related]
20. Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?
Rogers J; Mastroeni D; Leonard B; Joyce J; Grover A
Int Rev Neurobiol; 2007; 82():235-46. PubMed ID: 17678964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
